More news articles

New Pfizer UK leader as Nordkamp moves into European role

Ben Osborn to take on managing director role

BMS to test Vedanta’s bacterial therapy with Opdivo

Will be trialled in those with advanced or metastatic cancers

Roche's O’Day swaps big pharma for big biotech

Move to Gilead enforces reshuffle at neighbours Genentech

UK’s genomics leadership attracts IQVIA investment, regardless of Brexit

Invests in Genomics England alliance, plus clinical trials expansion

Biogen picks up another drug from wide-ranging Ionis alliance

Aims to follow success of Spinraza

As France protests, Sanofi takes axe to 670 jobs

Layoffs latest in restructuring programme

UK life sciences gets some Brexit relief with £1.3bn sector deal

Highlights commitments from Roche, IQVIA, Celgene and Autolus

Genomics England reaches 100,000th genome sequencing milestone

UK becomes world first to introduce whole genomic sequencing in clinics

Takeda secures investor backing for £46bn Shire takeover

The deal is expected to close early next year

CAR-Ts take centre stage as ASH18 comes to a close

Candidates from Allogene, Legend Biotech and Novartis were among the highlights

Dutch biotech Argenx claims $1.8bn licensing deal with J&J

Deal centres around blood cancer candidate cusatuzumab

Open Health merges with med comms services provider Peloton

The combined entity will fall under the Open Health brand

GSK buys cancer firm Tesaro for $5.1bn

Acquisition re-establishes US commercial operations in oncology

Amgen’s BCMA drug on course to challenge CAR-Ts in myeloma

BiTE will rival therapies from Bluebird, Celgene/Juno, J&J/Legend biotech

Grail to initiate largest ever UK cancer screening study

Will start testing on 50,000 people in early 2019

Regeneron’s early stage bispecific shows promise

Bispecifics and antibody drug conjugates will challenge CAR-Ts